In March, the research institute listed Pfizer’s health benefit price benchmark between $3,600 and $5,800. On Dec. 20, ICER updated this figure to be between $563 and $906.
Since the two-drug, five-day regimen became available in late 2021, the U.S. has bought the antiviral treatment for about $530 per packet. In 2023, though, pharmaceutical companies are planning to shift their COVID-19 vaccines and drugs to the commercial market.
ICER said the revised value for Paxlovid is based on “evidence suggesting lower risks for hospitalization among untreated patients and lower relative reduction in hospitalization with Paxlovid.”
Pfizer has also tentatively priced its COVID-19 vaccine to cost between $110 and $130 per dose, but some legislators have questioned the drafted price.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.